NCCN issues first guidelines for deep vein thrombosis treatment in cancer patients.
Susman
Ed
E
D000925:Anticoagulants / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D004334:Drug Administration Schedule; D000077425:Fondaparinux; D006077:Government Agencies; D006493:Heparin / Q000008:administration & dosage; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D011134:Polysaccharides / Q000008:administration & dosage; D017410:Practice Guidelines as Topic; D013514:Surgical Procedures, Operative / Q000009:adverse effects; D014481:United States; D020246:Venous Thrombosis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology* / Q000517:prevention & control
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D011134:Polysaccharides; D006493:Heparin; D000077425:Fondaparinux